Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
5.5%
Buyback spend (TTM)
N/A
Cumulative buybacks
$4.77B
Key takeaways
- Diluted share count is up 5.5% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Boston Scientific (BSX)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Boston Scientific (BSX)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Boston Scientific (BSX)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Boston Scientific (BSX)
Latest: $0.00
Overview
Boston Scientific (BSX) most recent annual buyback spend stands at $0.00 (2025).
Across 2020–2025 (5 years), Boston Scientific buyback spend produced a CAGR of -100.0% – with a net decline across the window.
Between 2005 and 2025, Boston Scientific buyback spend plunged 100.0%, falling from $734.00M to $0.00.
The record annual buyback spend stands at $734.00M, reached in 2005; the historical low of $0.00 was recorded in 1991.
Boston Scientific Buyback Spend 2025: $0.00
Boston Scientific buyback spend in 2025 was $0.00.
Boston Scientific Buyback Spend 2024: $0.00
Boston Scientific buyback spend in 2024 was $0.00.
Boston Scientific Buyback Spend 2023: $0.00
In 2023, Boston Scientific reported buyback spend of $0.00, plunged 100.0% below 2022.
Boston Scientific Buyback Spend 2022: $136.00M
Boston Scientific buyback spend in 2022 was $136.00M.
Boston Scientific Buyback Spend 2021: $0.00
Boston Scientific buyback spend in 2021 was $0.00.
See more financial history for Boston Scientific (BSX).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $299.00M | −$299.00M | — | 1.49B | +0.6% | |
| 2024 | $0.00 | $266.00M | −$266.00M | — | 1.49B | +1.5% | |
| 2023 | $0.00 | $233.00M | −$233.00M | — | 1.46B | +1.7% | |
| 2022 | $136.00M | $220.00M | −$84.00M | 0.21% | 1.44B | +0.4% | |
| 2021 | $0.00 | $194.00M | −$194.00M | — | 1.43B | +1.2% | |
| 2020 | $535.00M | $170.00M | $365.00M | 1.04% | 1.42B | +0.4% | |
| 2019 | $0.00 | $157.00M | −$157.00M | — | 1.41B | +0.7% | |
| 2018 | $0.00 | $140.00M | −$140.00M | — | 1.40B | +0.6% | |
| 2017 | $0.00 | $127.00M | −$127.00M | — | 1.39B | +1.1% | |
| 2016 | $0.00 | $116.00M | −$116.00M | — | 1.38B | +2.7% | |
| 2015 | $0.00 | $107.00M | −$107.00M | — | 1.34B | -0.5% | |
| 2014 | $125.00M | $103.00M | $22.00M | 0.71% | 1.35B | +0.5% | |
| 2013 | $500.00M | $105.00M | $395.00M | 3.13% | 1.34B | -4.7% | |
| 2012 | $600.00M | $108.00M | $492.00M | 7.67% | 1.41B | -7.4% | |
| 2011 | $492.00M | $128.00M | $364.00M | 6.38% | 1.52B | +0.1% | |
| 2010 | $0.00 | $150.00M | −$150.00M | — | 1.52B | +0.7% | |
| 2009 | $0.00 | $144.00M | −$144.00M | — | 1.51B | +0.6% | |
| 2008 | $0.00 | $138.00M | −$138.00M | — | 1.50B | +0.8% | |
| 2007 | $60.00M | $122.00M | −$62.00M | 0.35% | 1.49B | +16.7% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 1.27B | +52.1% | |
| 2005 | $734.00M | $0.00 | $734.00M | 3.61% | 0.84B | -2.2% | |
| 2004 | $360.00M | $0.00 | $360.00M | 1.22% | 0.86B | +1.6% | |
| 2003 | $570.00M | $0.00 | $570.00M | 1.84% | 0.84B | +1.7% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.83B | -0.2% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.83B | +1.3% | |
| 2000 | $222.00M | $0.00 | $222.00M | — | 0.82B | -0.6% | |
| 1999 | $127.00M | $0.00 | $127.00M | — | 0.82B | +6.2% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.78B | -2.9% | |
| 1997 | $187.00M | $0.00 | $187.00M | — | 0.80B | +0.5% | |
| 1996 | $63.80M | $0.00 | $63.80M | — | 0.80B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $57.40M | $0.00 | $57.40M | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$136.00M
- 2021$0.00
- 2020$535.00M
- 2019$0.00
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$125.00M
- 2013$500.00M
- 2012$600.00M
- 2011$492.00M
- 2010$0.00
- 2009$0.00
- 2008$0.00
- 2007$60.00M
- 2006$0.00
- 2005$734.00M
- 2004$360.00M
- 2003$570.00M
- 2002$0.00
- 2001$0.00
- 2000$222.00M
- 1999$127.00M
- 1998$0.00
- 1997$187.00M
- 1996$63.80M
- 1995$0.00
- 1994$0.00
- 1993$57.40M
- 1992$0.00
- 1991$0.00
Buybacks vs stock-based compensation for Boston Scientific (BSX)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Boston Scientific (BSX)
How Boston Scientific splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Boston Scientific, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.44B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation